Condition category
Pregnancy and Childbirth
Date applied
26/02/2018
Date assigned
16/04/2018
Last edited
16/04/2018
Prospective/Retrospective
Retrospectively registered
Overall trial status
Ongoing
Recruitment status
Recruiting

Plain English Summary

Background and study aims
Preeclampsia is a serious pregnancy complication which can threaten the life and well-being of both the mother and the baby. There is a simple method of identifying women who are at very high risk of developing preeclampsia. During a hospital visit at 35 – 36 weeks at pregnancy information is recorded about maternal characteristics (such as, age, weight and race) and medical history (such as, chronic hypertension, diabetes, previous pregnancies complicated by preeclampsia). A measurement is also taken of the woman’s blood pressure (MAP), an ultrasound machine measures the blood flow from the mother to the placenta (UTPI), and a blood sample is taken to measure the level of a protein produced by the placenta (PLGF). A computer program then calculates the woman’s chance of developing preeclampsia. Those women found to be at high risk are invited to participate in this study, which investigates whether the use of a drug called pravastatin can prevent the development of preeclampsia.

Who can participate?
Pregnant women age over 18 who are at high risk of preeclampsia

What does the study involve?
Participants are randomly allocated to take one capsule per day of either pravastatin or a matching placebo (dummy drug). Participants are asked to stop taking capsules at 41 weeks’ gestation or in the event of early delivery, at the onset of labour (maximum duration of 42 days). The women have a follow-up visit 6 weeks after delivery. Incidence of preeclampsia with delivery is assessed by examination of patient hospital records and patient interviews.

What are the possible benefits and risks of participating?
The benefit for women taking part in the study is that they will know whether they are at high risk for developing preeclampsia or not. Those found to be at high risk will have more close monitoring of their blood pressure and the growth of their baby and they will benefit from such closer monitoring irrespective of whether they are allocated to the pravastatin or placebo group. If the study finds that pravastatin is useful in preventing preeclampsia, the women will benefit from such treatment in a future pregnancy, because women that get preeclampsia in one pregnancy are at much higher risk of developing preeclampsia in a future pregnancy. Extensive studies have reported that statins are not harmful to the fetus.

Where is the study run from?
1. King's College Hospital (UK)
2. The Royal London Hospital (UK)
3. Medway Maritime Hospital (UK)
4. North Middlesex Hospital (UK)
5. Homerton University Hospital (UK)
6. Southend University Hospital (UK)
7. Spitalul Filantropia Bucharest (Romania)
8. Virgen de la Arrixaca (Spain)
9. Hospital Universitario La Paz (Spain)
10. Hospital de Torrejon (Spain)
11. Ospedale Maggiore Policlinico (Italy)
12. CHU Brugmann (Belgium)

When is the study starting and how long is it expected to run for?
December 2016 to March 2020

Who is funding the study?
Fetal Medicine Foundation (UK)

Who is the main contact?
Prof. Kypros Nicolaides
eliza.tylki@nhs.net

Trial website

Contact information

Type

Scientific

Primary contact

Prof Kypros Nicolaides

ORCID ID

Contact details

Fetal Medicine Research Institute
King’s College Hospital
London
SE5 8BB
United Kingdom
+44 (0)2032998256
eliza.tylki@nhs.net

Additional identifiers

EudraCT number

2016-005206-19

ClinicalTrials.gov number

Protocol/serial number

33496

Study information

Scientific title

Randomised controlled trial with pravastatin versus placebo for prevention of preeclampsia

Acronym

STATIN

Study hypothesis

Preeclampsia (PE) is an important cause of maternal and perinatal mortality and morbidity. A major challenge in modern obstetrics is early identification of pregnancies at high risk of PE and undertaking the necessary measures to reduce the incidence of the disease. Extensive research has demonstrated that the development of PE can be predicted by a combination of maternal demographic characteristics and medical and obstetric history and biophysical markers including uterine artery pulsatility index (PI) and mean arterial pressure (MAP) and biochemical markers including maternal serum placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFLT-1). Although screening at 11-13, 20-24 and 30-34 weeks is effective at identifying pregnancies at high-risk of developing PE at < 37 weeks’ gestation (preterm-PE) the performance of screening for term-PE is poor. Large multicentre studies have shown that although adverse outcomes for the mother and baby are more serious with preterm-PE the contribution of term-PE to such adverse outcomes is at least as high because the condition is much more common (incidence 0.5-0.7% for preterm-PE and 2-2.5% for term-PE). For example, in half of the maternal deaths from hypertensive disorders of pregnancy in the UK and Ireland at 2009-2014, the death occurred at > 37 weeks gestation. Effective screening for term-PE can be achieved by a combination of maternal factors, MAP, PLGF and sFLT-1 at the time of a routine ultrasound scan to monitor fetal growth at 35-37 weeks of gestation. The objective of this study is to examine if the prophylactic use of pravastatin from 35-37 weeks’ gestation in women at increased risk for term-PE can reduce the incidence and severity of the disease.

Ethics approval

London - London Bridge Research Ethics Committee, 20/02/2017, ref: 17/LO/0130

Study design

Randomised; Both; Design type: Prevention, Drug, Cohort study

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Trial setting

Hospitals

Trial type

Prevention

Patient information sheet

Not available in web format, please use the contact details to request a patient information sheet: Anca Ciobanu: anca.ciobanu@nhs.net; Moritz Döbert: moritz.dobert@nhs.net

Condition

Specialty: Reproductive health and childbirth, Primary sub-specialty: General Obstetrics/ Midwifery; UKCRC code/ Disease: Reproductive Health and Childbirth/ Oedema, proteinuria and hypertensive disorders in pregnancy, childbirth and the puerperium

Intervention

This is a double-blind randomised placebo-controlled trial for which the eligible participants will be identified by a screening study. In the participating centres in Spain, Italy, Belgium, Romania and the UK, all women attending for their routine hospital visit in pregnancy at 35+0-36+6 weeks’ gestation will be screened to identify a high-risk group for development of PE. In this visit the trialists will record maternal characteristics and medical history, measure the maternal MAP and serum PLGF and sFLT-1 and on the basis of these results estimate the risk for term-PE. Women that are screened positive for term-PE will be invited to participate in the randomised trial of pravastatin. Participants will take one capsule per day of either pravastatin 20mg or matching placebo. Participants will be asked to stop taking capsules at 41 weeks’ gestation or in the event of early delivery, at the onset of labour (maximum duration of 42 days). The women will have a follow-up visit 6 weeks after delivery.

Intervention type

Drug

Phase

Not Applicable

Drug names

Pravastatin

Primary outcome measures

Incidence of PE with delivery, assessed by examination of patient hospital records and patient interviews

Secondary outcome measures

Assessed by examination of patient hospital records and patient interviews:
1. Adverse outcome of pregnancy at any gestation
2. Adverse outcome of pregnancy at >37 weeks’ gestation
3. Stillbirth or neonatal death
4. Neonatal morbidity
5. Neonatal therapy
6. Incidence of low birth weight
7. sFLT-1 and PLGF value at 1 and 3 weeks after the onset of treatment
8. Pravastatin safety assessment during pregnancy: at 1 and 2 weeks after the onset of treatment, at term, 6 weeks after delivery

Overall trial start date

20/12/2016

Overall trial end date

30/03/2020

Reason abandoned

Eligibility

Participant inclusion criteria

1. Pregnant women without established preeclampsia
2. Singleton pregnancy
3. Live fetus at 35+0-36+6 weeks’ gestation
4. Informed and written consent
5. Age >18 years
6. Not unconscious or very ill
7. No serious mental illness
8. No learning difficulties
9. Fluent in local language or translation by interpreter
10. No major fetal abnormality
11. No statin use within 28 days prior to randomisation
12. None of the following contraindications for statin therapy:
12.1. Hypersensitivity to pravastatin or any component of the product
12.2. Lactose intolerance
12.3. Current or previous cancer
12.4. Previous solid organ transplant
12.5. Active liver disease (acute hepatitis, chronic active hepatitis) in the past 6 months
12.6. Chronic renal disease/insufficiency with baseline serum creatinine >1.5mg/dL
12.7. History of myopathy or rhabdomyolysis
12.8. ALT and/or AST levels ≥ 2 x the upper limit of normal
12.9. Creatine kinase levels ≥ 5 x the upper limit of normal
12.10. Concurrent and chronic (>6 months) use of medications with potential drug interactions with statins, such as immunosuppressive drugs, fibrates, gemfibrozil, niacin, protease inhibitors, efavirenz (non-nucleoside reverse transcriptase inhibitor), erythromycin, clarithromycin, itraconazole, cholestyramine, digoxin, rifampicin (patients will not be excluded if the drug has been discontinued, or is prescribed for a short duration of time)
12.11. Participating in another intervention study that influences the outcomes of this study

Inclusion criteria for participant selection for RCT:
1. Same as for screening
2. Identified at screening as being at high-risk for term-PE by the algorithm combining maternal history and characteristics, MAP, PLGF and sFLT-1
3. Informed and written consent

Participant type

Patient

Age group

Adult

Gender

Female

Target number of participants

Planned Sample Size: 1120; UK Sample Size: 750

Participant exclusion criteria

For the randomised trial, same as for screening, but in addition:
1. Major fetal abnormality
2. Women with established PE
3. Statin use within 28 days prior to randomisation
4. Women with contraindications for statin therapy:
4.1. Hypersensitivity to pravastatin or any component of the product
4.2. Lactose intolerance
4.3. Current or previous cancer
4.4. Previous solid organ transplant
4.5. Active liver disease (acute hepatitis, chronic active hepatitis) in the past 6 months
4.6. Chronic renal disease/insufficiency with baseline serum creatinine > 1.5mg/dL
4.7. History of myopathy or rhabdomyolysis
4.8. ALT and/or AST levels > = 2 x the upper limit of normal
4.9. Creatine kinase levels > = 5 x the upper limit of normal
4.10. Concurrent and chronic (> 6 months) use of medications with potential drug interactions with statins, such as immunosuppressive drugs, fibrates, gemfibrozil, niacin, protease inhibitors, efavirenz (non-nucleoside reverse transcriptase inhibitor), erythromycin, clarithromycin, itraconazole, cholestyramine, digoxin, rifampicin (patients will not be excluded if the drug has been discontinued, or is prescribed for a short duration of time)
5. Participating in another intervention study that influences the outcomes of this study

Recruitment start date

30/03/2018

Recruitment end date

30/03/2019

Locations

Countries of recruitment

Belgium, Italy, Romania, Spain, United Kingdom

Trial participating centre

King‘s College Hospital
Windsor Walk 16-20
London
SE5 8BB
United Kingdom

Trial participating centre

The Royal London Hospital
Whitechapel Rd Whitechapel
London
E1 1BB
United Kingdom

Trial participating centre

Medway Maritime Hospital
Windmill Road
Gillingham
ME7 5NY
United Kingdom

Trial participating centre

North Middlesex Hospital
Sterling Way
London
N18 1QX
United Kingdom

Trial participating centre

Homerton University Hospital
Homerton Row
London
E9 6SR
United Kingdom

Trial participating centre

Southend University Hospital
Prittlewell Chase
Westcliff-on-Sea
SS0 0RY
United Kingdom

Trial participating centre

Spitalul Filantropia Bucharest
Bulevardul Ion Mihalache 11
Bucharest
01117
Romania

Trial participating centre

Virgen de la Arrixaca
Ctra. Madrid-Cartagena, s/n, El Palmar
Murcia
30120
Spain

Trial participating centre

Hospital Universitario La Paz
Paseo de la Castellana, 261
Madrid
28046
Spain

Trial participating centre

Hospital de Torrejon
Calle Mateo Inurria, s/n, Torrejón de Ardoz
Madrid
28850
Spain

Trial participating centre

Ospedale Maggiore Policlinico
Via Francesco Sforza, 35
Milano
20122
Italy

Trial participating centre

CHU Brugmann
Place A.Van Gehuchten 4
Brussels
1020
Belgium

Sponsor information

Organisation

Fundacion para la Formacion e Investigacion Sanitaria (Spain) (Primary Sponsor)

Sponsor details

C / Luis Fontes Pagán No. 9
1st floor
Murcia
30003
Spain

Sponsor type

Hospital/treatment centre

Website

Organisation

King’s College Hospital (Secondary Sponsor)

Sponsor details

Sponsor responsibilities for Trial Management are delegated to the FMF for sites in the UK
Belgium
Italy and Romania by the regulator
primary sponsor
c/o Prof Kypros Nicolaides
Fetal Medicine Research Institute
London
SE5 8BB
United Kingdom
+44 (0)2032998256
eliza.tylki@nhs.net

Sponsor type

Hospital/treatment centre

Website

Funders

Funder type

Charity

Funder name

Fetal Medicine Foundation

Alternative name(s)

Funding Body Type

private sector organisation

Funding Body Subtype

foundation

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Planned publication in high-impact peer reviewed journals.

IPD sharing statement
The data sharing plans for the current study are unknown and will be made available at a later date.

Intention to publish date

30/03/2021

Participant level data

To be made available at a later date

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes